Back to Search
Start Over
Effect of colchicine on inflammatory markers in patients with coronary artery disease: A meta-analysis of clinical trials.
- Source :
-
European Journal of Pharmacology . Jul2022, Vol. 927, pN.PAG-N.PAG. 1p. - Publication Year :
- 2022
-
Abstract
- Whether colchicine reduces the levels of high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) remains uncertain. Therefore, this systematic review and meta-analysis were conducted to evaluate the overall effect of colchicine treatment on hs-CRP and IL-6 levels in patients with coronary artery disease (CAD). PubMed/Medline, Embase, and the Cochrane Central Register of Controlled Trials were searched for studies published before October 2021. Clinical trials in patients with CAD with reports of hs-CRP and IL-6 level changes before and after colchicine intervention were included. In total, 11 trials on hs-CRP and two trials on IL-6 were included in this meta-analysis. Compared with that in the control group, colchicine treatment was significantly associated with decreased hs-CRP levels (weighted mean differences [WMDs], −0.81 mg/L; 95% confidence interval [CI], −1.34 to −0.28 mg/L; P = 0.003) in patients with CAD. Besides, the levels of IL-6 were significantly reduced in colchicine users compared to that of placebo (WMD, −1.28 pg/mL; 95% CI, −2.35 to −0.21 pg/mL; P = 0.02). In a subgroup analysis, colchicine led to a significant reduction in hs-CRP levels in studies with duration of intervention >7 days (WMD, −0.65 mg/L; 95% CI, −1.08 to −0.21 mg/L; P = 0.004) and studies with baseline hs-CRP levels ≥3.0 mg/L (WMD, −0.99 mg/L; 95% CI, −1.92 to −0.06 mg/L; P = 0.04). Colchicine intervention was associated with a reduction in hs-CRP and IL-6 levels in patients with CAD. Future investigations are required to verify the effect of colchicine on inflammatory markers and clarify the potential mechanisms of the cross talk between colchicine, inflammation, and cardiovascular outcomes. • Comparing with that in the control group, colchicine intervention was associated with a reduction in hs-CRP and IL-6 levels in patients with coronary artery disease. • The administration of 1 mg colchicine daily could lead to a more substantial reduction in hs-CRP levels than that of a 0.5 mg daily dose. • Patients with the following characteristics had a trend of benefiting from colchicine: ACS, duration >7 days, and baseline hs-CRP level ≥3.0 mg/L. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00142999
- Volume :
- 927
- Database :
- Academic Search Index
- Journal :
- European Journal of Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 157386613
- Full Text :
- https://doi.org/10.1016/j.ejphar.2022.175068